KCM
GILD icon

KLK Capital Management’s Gilead Sciences GILD Stock Holding History

KLK Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-245,011
Closed -$245K – 48
2021
Q3 		$245K Buy
+245,011
New +$17.2M 0.22% 49

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KLK Capital Management's GILD Position: Q4 2021 in Review

KLK Capital Management sold out of Gilead Sciences (GILD) in Q4 2021, closing a stake of 245,011 shares — an estimated $245K sold.

KLK Capital Management first reported a position in GILD in Q3 2021 and held it in 1 quarter. The position peaked at $245K in Q3 2021. 1,682 funds tracked by Wall St. Rank hold GILD as of Q4 2021.

  • KLK Capital Management reported no remaining Gilead Sciences position as of Q4 2021 after selling out during the quarter.
  • KLK Capital Management sold 245,011 Gilead Sciences shares in Q4 2021, an estimated $245K.
  • KLK Capital Management first reported a position in Gilead Sciences in Q3 2021 and held it in 1 quarter.
  • KLK Capital Management's Gilead Sciences position peaked at $245K in Q3 2021.
  • 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.

Based on KLK Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.